If your research investigates the complex interplay between lipid metabolism, growth hormone (GH) secretion, and tissue regeneration, the\u00a0<\/span>Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)<\/span><\/strong>\u00a0offers a sophisticated, multi\u2011pathway experimental platform. This 12\u202fmg formulation combines three distinct and well\u2011characterised research peptides\u2014<\/span>Fragment 176-191<\/span><\/strong>\u00a0(a lipolytic fragment of human growth hormone),\u00a0<\/span>CJC-1295<\/span><\/strong>\u00a0(a modified GHRH analog), and\u00a0<\/span>Ipamorelin<\/span><\/strong> (a selective ghrelin receptor agonist)\u2014each acting through complementary mechanisms to modulate metabolic signalling and the GH axis.<\/span><\/p>\n By targeting the GHRH receptor, the ghrelin receptor, and peripheral lipid metabolism, this blend allows researchers to model the synergistic interplay between these pathways, providing deeper insight into the regulatory circuits that govern metabolic homeostasis, growth hormone pulsatility, and tissue repair.<\/span><\/p>\n At\u00a0<\/span>Wuhan Top Miracle Peptides<\/span><\/strong>, we supply high\u2011purity\u00a0<\/span>Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)<\/span><\/strong>\u00a0to research institutions and wholesale buyers across the\u00a0<\/span>United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA<\/span><\/strong>. Every batch is lyophilised, HPLC\u2011verified to \u226598% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into metabolic regulation, GH signalling, and tissue regeneration begin with uncompromising quality<\/span>.<\/span><\/p>\n To fully appreciate the research potential of the\u00a0<\/span>Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)<\/span><\/strong>, it is essential to understand the distinct yet complementary mechanisms of its three components<\/span>.<\/span><\/p>\n Fragment 176-191, also known as AOD9604, is a synthetic peptide corresponding to the C\u2011terminal region (residues 176\u2011191) of human growth hormone (hGH)<\/span>. It has been hypothesised to play a pivotal role in metabolic regulation and tissue regeneration<\/span>.<\/span><\/p>\n Unlike full\u2011length hGH, Fragment 176\u2011191 selectively targets pathways involved in lipid metabolism without significantly impacting insulin or IGF\u20111 levels<\/span>. The peptide is believed to promote lipolysis (the breakdown of stored fat) while inhibiting lipogenesis (the formation of new fat deposits)<\/span>. It may target beta\u20113 adrenergic receptors (ADRB3), potentially inducing weight loss downstream and boosting fat burning in adipose tissue cells<\/span>. A 2008 study published in the\u00a0<\/span>Journal of Endocrinology<\/span><\/em>\u00a0found that GH fragment 176-191 increased lipid oxidation in test systems and did not stimulate IGF\u20111 or GH signalling like full GH<\/span>. Fragment 176-191 exhibits lipolytic activity similar to that of growth hormone, without the accompanying hyperglycemia<\/span>.<\/span><\/p>\n CJC-1295 is a synthetic peptide derivative of growth hormone\u2011releasing hormone (GHRH)<\/span>. It is a tetrasubstituted form of hGRF(1\u201129) that activates the GHRH receptor on the anterior pituitary<\/span>. Unlike CJC\u20111295\u2011DAC, CJC\u20111295 does not contain a drug affinity complex (DAC) moiety and has a shorter half\u2011life than the DAC\u2011conjugated version<\/span>. Research indicates that CJC\u20111295 is a stable and active hGRF(1\u201129) analog with an extended plasma half\u2011life<\/span>. It increases the secretion of growth hormone in primary rat anterior pituitary cells and into rat blood when administered subcutaneously<\/span>. Its molecular formula is\u00a0<\/span>C\u2081\u2085\u2082H\u2082\u2085\u2082N\u2084\u2084O\u2084\u2082<\/span><\/strong>, with a molecular weight of approximately\u00a0<\/span>3,367.9 g\/mol<\/span><\/strong>.<\/span><\/p>\n Ipamorelin is a synthetic pentapeptide and a potent, selective agonist of the ghrelin receptor (GHS\u2011R1a)<\/span>. It was first described in a 1998 paper in the\u00a0<\/span>European Journal of Endocrinology<\/span><\/em>\u00a0as “the first selective growth hormone secretagogue”<\/span>. Its defining pharmacological advantage is GH stimulation without elevating cortisol, ACTH, or prolactin<\/span>. Ipamorelin binds to COS\u20117 cells expressing GHS\u2011R1a with a Ki of 63.4 nM<\/span>. It induces inositol\u20111,4,5\u2011triphosphate (IP\u2083) accumulation in cells expressing GHS\u2011R1a with an EC\u2085\u2080 of 46.9 nM<\/span>. Its molecular formula is\u00a0<\/span>C\u2083\u2088H\u2084\u2089N\u2089O\u2085<\/span><\/strong>, with a molecular weight of approximately\u00a0<\/span>711.8 g\/mol<\/span><\/strong>.<\/span><\/p>\n The scientific rationale for combining Fragment 176-191, CJC\u20111295, and Ipamorelin lies in their convergent yet distinct mechanisms<\/span>:<\/span><\/p>\n Fragment 176\u2011191<\/span><\/strong>\u00a0provides a peripheral metabolic signal, promoting lipolysis and inhibiting lipogenesis through pathways that may involve beta\u20113 adrenergic receptors<\/span>.<\/span><\/p>\n<\/li>\n CJC\u20111295<\/span><\/strong>\u00a0provides the primary stimulus to initiate GH synthesis and release by activating the classical GHRH receptor pathway<\/span>.<\/span><\/p>\n<\/li>\n Ipamorelin<\/span><\/strong>\u00a0enhances the amplitude of that response by engaging the ghrelin\/secretagogue receptor system<\/span>.<\/span><\/p>\n<\/li>\n<\/ul>\n This triple\u2011pathway activation has been suggested by researchers to potentially synergistically enhance and regulate growth hormone concentration and maintain equilibrium levels<\/span>. The blend may be explored in experimental models examining metabolic equilibrium and physiological resilience<\/span>.<\/span><\/p>\n The\u00a0<\/span>Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)<\/span><\/strong>\u00a0is a versatile tool with applications spanning several domains of metabolic and endocrine research.<\/span><\/p>\n Fragment 176\u2011191’s ability to stimulate lipolysis and inhibit lipogenesis makes this blend a valuable tool for studying lipid metabolism<\/span>. Research applications include:<\/span><\/p>\n Lipolysis Signalling Pathways:<\/span><\/strong>\u00a0Investigating the molecular mechanisms that trigger the breakdown of triglycerides in adipocytes<\/span>.<\/span><\/p>\n<\/li>\n Adipocyte Metabolism:<\/span><\/strong>\u00a0Studying the regulation of lipid storage and mobilisation in adipose tissue<\/span>.<\/span><\/p>\n<\/li>\n Metabolic Homeostasis:<\/span><\/strong>\u00a0Exploring how modulation of lipid metabolism affects overall metabolic equilibrium<\/span>.<\/span><\/p>\n<\/li>\n Obesity Research:<\/span><\/strong>\u00a0Investigating the peptide’s potential to impact energy expenditure and fat oxidation pathways<\/span>.<\/span><\/p>\n<\/li>\n<\/ul>\n The CJC\u20111295 and Ipamorelin components provide a powerful model for investigating the hypothalamic\u2011pituitary\u2011somatotropic axis. Researchers can use it to study:<\/span><\/p>\n Synergistic GH Secretion:<\/span><\/strong>\u00a0The effects of combined GHRH and ghrelin receptor activation on GH synthesis and pulsatile release<\/span>.<\/span><\/p>\n<\/li>\n Receptor Pharmacology:<\/span><\/strong>\u00a0The distinct contributions of GHRH\u2011mediated and ghrelin\u2011mediated signalling to overall GH secretion<\/span>.<\/span><\/p>\n<\/li>\n Pulsatile Dynamics:<\/span><\/strong>\u00a0The dynamics of GH pulse amplitude and frequency in response to dual\u2011pathway stimulation.<\/span><\/p>\n<\/li>\n<\/ul>\n Fragment 176\u2011191 has been hypothesised to impact cellular repair and regeneration processes, particularly in tissues affected by injury or degeneration<\/span>. Research applications include:<\/span><\/p>\n Collagen Synthesis:<\/span><\/strong>\u00a0Studying the peptide’s potential to support collagen synthesis and extracellular matrix remodelling<\/span>.<\/span><\/p>\n<\/li>\n Cartilage Repair:<\/span><\/strong>\u00a0Exploring the peptide’s hypothesised impact on cartilage repair, which may provide insights into interventions to address degenerative joint conditions<\/span>.<\/span><\/p>\n<\/li>\n Bone Remodelling:<\/span><\/strong>\u00a0Investigating pathways involved in bone formation and resorption, with potential support for the mineralisation of bone<\/span>.<\/span><\/p>\n<\/li>\n<\/ul>\n Growth hormone secretagogues like CJC\u20111295 and Ipamorelin activate IGF\u20111 signalling and satellite cell repair<\/span>. Research applications include:<\/span><\/p>\n Satellite Cell Activation:<\/span><\/strong>\u00a0Investigating the role of GH signalling in activating satellite cells for muscle repair and regeneration.<\/span><\/p>\n<\/li>\n Cellular Differentiation and Proliferation:<\/span><\/strong>\u00a0Studying how enhanced GH levels may encourage these processes in various tissue types.<\/span><\/p>\n<\/li>\n Regenerative Science:<\/span><\/strong>\u00a0Exploring the peptide’s potential to support tissue regeneration<\/span>.<\/span><\/p>\n<\/li>\n<\/ul>\n Accurate characterisation of the\u00a0<\/span>Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)<\/span><\/strong>\u00a0is essential for reproducible experimental design<\/span>.<\/span><\/p>\nWhat Is the Fragment 176-191 & CJC-1295 & Ipamorelin Blend and How Does It Work?<\/span><\/h2>\n
Fragment 176-191 (AOD9604): The Lipolytic HGH Fragment<\/span><\/h3>\n
CJC-1295: The Long\u2011Acting GHRH Analog<\/span><\/h3>\n
Ipamorelin: The Selective Ghrelin Receptor Agonist<\/span><\/h3>\n
Mechanism of Synergy: Triple\u2011Pathway Activation<\/span><\/h3>\n
\n
Key Research Applications for the Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)<\/span><\/h2>\n
1. Metabolic & Lipid Research<\/span><\/h3>\n
\n
2. Growth Hormone Axis & Pituitary Function Studies<\/span><\/h3>\n
\n
3. Tissue Repair & Regeneration Research<\/span><\/h3>\n
\n
4. Cellular Senescence & Regenerative Research<\/span><\/h3>\n
\n
Chemical & Physical Specifications for Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)<\/span><\/h2>\n
\n\n
\n Parameter<\/span><\/th>\n Specification<\/span><\/th>\n<\/tr>\n<\/thead>\n\n \n Common Names<\/span><\/strong><\/td>\n Fragment 176-191 + CJC-1295 + Ipamorelin Blend, AOD9604 + Mod GRF 1-29 + Ipamorelin<\/span><\/td>\n<\/tr>\n \n Contents<\/span><\/strong><\/td>\n Fragment 176-191 (6mg), CJC-1295 NO DAC (3mg), Ipamorelin (3mg)<\/span><\/td>\n<\/tr>\n \n Fragment 176-191 Sequence<\/span><\/strong><\/td>\n C\u2011terminal fragment of hGH (residues 176\u2011191)<\/span><\/td>\n<\/tr>\n \n